---

Parvovirus in Dogs and Cats

A Complete Veterinary Reference

---

1. VIROLOGY & CLASSIFICATION

Family & Taxonomy

Strains & Variants

• CPV-2 (original): No longer circulates; replaced by antigenic variants
• CPV-2a (1979–80): First major variant; can infect cats
• CPV-2b (1984): More pathogenic than 2a; predominant in many regions
• CPV-2c (early 2000s): Most recently characterized; can infect cats; associated with more severe disease in some studies; dominant in parts of Europe, South America, and now widespread globally

• Extremely stable in the environment — survives months to years at room temperature on contaminated surfaces, soil, and fomites
• Resistant to most disinfectants except bleach (1:30 dilution), accelerated hydrogen peroxide, potassium peroxymonosulfate, and formaldehyde
• Resistant to heat, cold, pH extremes, and many common detergents
• Requires rapidly dividing cells for replication (uses host cell DNA polymerase during S-phase)

---

2. EPIDEMIOLOGY

Canine Parvovirus

• Worldwide distribution — one of the most common infectious diseases of dogs
• Host range: Domestic dogs (Canis lupus familiaris), wolves, coyotes, raccoons, foxes, mink; CPV-2a/2b/2c also infect domestic cats
• Age susceptibility: Puppies 6 weeks to 6 months most severely affected; maternal antibody wanes at 6–8 weeks in most breeds, creating a window of susceptibility
• Breed predisposition: Rottweiler, Doberman Pinscher, American Pit Bull Terrier, Labrador Retriever, German Shepherd — these breeds may have attenuated immune responses or genetic susceptibility; Rottweilers and Dobermans have significantly higher mortality
• Seasonality: Year-round, but peaks in late spring, summer, and fall (correlates with breeding seasons and litter movement)
• Transmission: Primarily feco-oral — direct contact with infected feces, contaminated environment, fomites (shoes, clothing, instruments), or via the oro-nasal route
• Shedding: Infected dogs shed virus in feces starting 3–4 days post-infection, 1–2 days before clinical signs; shedding peaks at days 4–7 and continues for up to 2–3 weeks post-recovery
• Incubation period: 3–7 days (range 4–14 days)

Feline Panleukopenia Virus

• Worldwide distribution — historically one of the most devastating feline diseases; less common now due to vaccination
• Host range: All members of Felidae; also mink, raccoons (Procyon lotor), coatimundi, ferrets
• Age susceptibility: Kittens 3–5 months most severely affected; neonates affected differently (cerebellar hypoplasia)
• Transmission: Feco-oral, direct contact, fomites; also via infected urine, vomit, and fleas (mechanical vector)
• Incubation period: 2–10 days (typically 4–6 days)

---

3. PATHOGENESIS

The Core Requirement: Dividing Cells

Canine Parvovirus — Step-by-Step Pathogenesis

Oral/nasal exposure
        ↓
Virus replicates in oropharyngeal lymphoid tissue (tonsils, pharyngeal lymph nodes)
        ↓  (Days 1–3)
Primary viremia — virus enters bloodstream via lymphatics
        ↓
Virus seeds rapidly dividing tissues:
  • Bone marrow (hematopoietic progenitor cells)
  • Intestinal crypt epithelium (most clinically significant)
  • Thymus (especially in neonates/young puppies)
  • Lymphoid tissue throughout body
        ↓
Destruction of intestinal crypt cells
  → Villi collapse (no new enterocytes to replace sloughed tips)
  → Loss of mucosal integrity → "leaky gut"
  → Malabsorption + fluid loss
  → Bacterial translocation (E. coli, Clostridium, Campylobacter, Salmonella)
  → Endotoxemia / septicemia
        ↓
Bone marrow suppression
  → Neutropenia (5–6 days post-infection)
  → Lymphopenia (very early, within first 24–48 hrs)
  → Thrombocytopenia
        ↓
Combined: Hemorrhagic diarrhea + Sepsis + Endotoxemia

Myocarditis Form (Neonatal/Perinatal)

• Occurs in puppies infected in utero or < 4 weeks of age (before 4 weeks, cardiomyocytes are still actively dividing)
• Virus replicates in rapidly dividing myocardial cells → acute myocardial necrosis
• Rarely seen today due to widespread vaccination; most reported in unvaccinated populations in developing countries
• Pups die acutely of congestive heart failure ("fading puppy") or develop dilated cardiomyopathy weeks to months later

Feline Panleukopenia — Pathogenesis

• External granular layer of cerebellum is actively proliferating in late gestation and first 2 weeks of life
• FPV destroys these cells → permanent cerebellar hypoplasia
• Kittens are born or develop: wide-based stance, intention tremor, hypermetria, dysmetria
• Non-progressive — kittens do not worsen after initial signs; many live quality lives

---

4. CLINICAL SIGNS

Canine Parvoviral Enteritis

• Lethargy, depression, anorexia
• Fever (39.5–41°C / 103–106°F) — may be absent or subnormal in severe cases (hypothermia = poor prognosis)

• Vomiting — often profuse, may be bilious; can precede diarrhea
• Diarrhea — initially yellow/gray liquid; progresses to hemorrhagic ("tomato soup") in many cases; profuse, fetid odor
• Abdominal pain — may be severe
• Profound dehydration (5–12%)
• Hematochezia or melena

• Severe leukopenia (especially neutropenia and lymphopenia)
• Secondary bacterial infection / sepsis
• Endotoxemia → septic shock → SIRS (Systemic Inflammatory Response Syndrome)
• Disseminated Intravascular Coagulation (DIC) in severe cases
• Hypoproteinemia (protein-losing enteropathy)
• Hypokalemia, hypoglycemia (especially in small breeds and young puppies)

Feline Panleukopenia

• Death within 12–24 hours with minimal or no prodromal signs
• Seen in kittens; may be found dead

• High fever (40–41.7°C / 104–107°F)
• Profound depression, complete anorexia
• Vomiting (often bile-stained)
• Diarrhea — may be hemorrhagic, watery; less consistent than in CPV (some cats have no diarrhea)
• Severe dehydration
• Cats may sit hunched over water bowl (due to nausea/dehydration) but not drink
• Abdominal pain
• Panleukopenia: severe drop in ALL white blood cell lines

• Mild malaise, partial anorexia, mild fever
• May go unnoticed; self-limiting

• Kittens normal at birth but signs appear when they begin to walk (2–3 weeks)
• Intention tremor (worsens with movement, disappears at rest)
• Hypermetria, dysmetria, wide-based stance
• No progression; cognitive function normal

---

5. DIAGNOSIS

Clinical Diagnosis

• Signalment: Unvaccinated or incompletely vaccinated puppy/kitten
• History: Exposure to other dogs, shelter, pet store, park
• Classic signs: Acute onset vomiting + hemorrhagic diarrhea + leukopenia

Laboratory Findings

Pearl: Lymphopenia often precedes all other signs. A WBC >5,000 cells/μL 24 hours after onset makes CPV/FPV less likely.

• Hypoalbuminemia (protein-losing enteropathy)
• Hypokalemia (vomiting + diarrhea)
• Hypoglycemia (especially neonates; endotoxemia inhibits gluconeogenesis)
• Elevated BUN (prerenal azotemia from dehydration; occasionally renal involvement)
• Elevated ALT/AST (hepatic inflammation or sepsis)

• Usually concentrated (prerenal)
• Proteinuria possible

Specific Tests

• Most commonly used test in clinical practice
• Detects CPV/FPV antigen in feces
• Sensitivity: ~50–80%; Specificity: ~97–99%
• False negatives common early in infection (before peak shedding), or late in course
• False positives reported within 5–15 days of modified-live vaccination (MLV) — historically more relevant with older vaccines; less common with newer vaccines
• Test should be run on fresh rectal swab or fecal sample

• Most sensitive and specific test available
• Can detect virus when ELISA is negative
• Can differentiate vaccine strain vs. field strain (real-time PCR with strain-specific assays)
• Can identify CPV-2a, 2b, 2c variants
• Can be run on feces, intestinal tissue (post-mortem)
• Preferred for confirmation when ELISA is negative but suspicion is high

• Classic virology tests; less used clinically
• HA detects viral antigen; HI measures antibody titers
• Useful in research and seroprevalence studies

• Useful for assessing vaccination status or prior exposure
• Serum neutralization or HI titer ≥1:80 considered protective
• Less useful for acute diagnosis (need paired samples)

• Classic diagnostic method; not used routinely
• Identifies parvovirus particles in feces

• Reference standard for research; not clinically practical
• Requires specific cell lines (CRFK cells for FPV; A72 or NLFK cells for CPV)

Post-Mortem Findings

• Intestines: dilated, flaccid, hemorrhagic; "paint brush" hemorrhages on serosal surface
• Intestinal contents: watery, hemorrhagic, necrotic debris
• Mesenteric lymph nodes: enlarged, congested, hemorrhagic
• Thymus: marked atrophy (especially in puppies) — "thymic atrophy" pathognomonic
• Bone marrow: pale, hypocellular

• Intestinal crypt necrosis — crypt cells show karyomegaly, intranuclear inclusions, then complete destruction
• Villous atrophy and collapse
• Intranuclear inclusion bodies in crypt epithelial cells (early infection)
• Depletion of lymphoid follicles in Peyer's patches, lymph nodes, thymus, spleen
• Bone marrow: depletion of myeloid and erythroid precursors

---

6. DIFFERENTIAL DIAGNOSES

Dogs

Cats

---

7. TREATMENT

Goals of Treatment

1. Correct dehydration and electrolyte imbalances
2. Control vomiting
3. Prevent/treat secondary bacterial infection
4. Provide nutritional support
5. Manage complications (hypoglycemia, DIC, protein loss)

No specific antiviral therapy is licensed for CPV/FPV. Treatment is supportive and intensive.

---

Fluid Therapy — The Cornerstone

Total fluid requirement = Deficit + Maintenance + Ongoing losses

Deficit (L) = Body weight (kg) × % dehydration
Maintenance = 40–60 mL/kg/day
Ongoing losses = estimate from vomiting/diarrhea volume

• Fresh Frozen Plasma (FFP): 10–20 mL/kg IV — provides albumin, clotting factors, and immunoglobulins (Note: provides minimal immunoglobulin against CPV per current evidence)
• Hetastarch or Vetstarch: 5–20 mL/kg IV as CRI; maintain oncotic pressure

---

Antiemetics

• Mechanism: NK-1 receptor antagonist; acts centrally (CRTZ and vomiting center) AND peripherally (GI)
• Dose: 1 mg/kg IV/SQ q24h (dogs); 1 mg/kg SQ q24h (cats)
• Preferred over other antiemetics due to also reducing visceral pain
• Evidence: significantly reduces vomiting episodes and duration in CPV

• Mechanism: 5-HT3 receptor antagonist; central and peripheral
• Dose: 0.1–0.2 mg/kg IV slow bolus q8–12h; or CRI 0.1–0.2 mg/kg/hr
• Excellent for refractory vomiting; can be combined with maropitant

• Mechanism: Dopamine antagonist + prokinetic
• Dose: 0.2–0.5 mg/kg IV/SQ q6–8h; or CRI 1–2 mg/kg/day
• Less effective for CPV-associated vomiting than maropitant/ondansetron; may be useful as prokinetic when ileus is present
• Avoid in GI obstruction

---

Antimicrobial Therapy

• Intestinal mucosal barrier breakdown
• Neutropenia creating high risk of bacteremia/sepsis
• Gram-negative bacterial translocation

• Ampicillin 22 mg/kg IV q6–8h (covers Gram-positive and anaerobes) +
• Enrofloxacin 5–10 mg/kg IV/SQ q24h (covers Gram-negative) — use with caution in puppies <8 months (cartilage toxicity risk) and cats (use with extreme caution; narrow margin of safety)
  • Alternative: Marbofloxacin in cats

• Ampicillin-sulbactam 22–30 mg/kg IV q8h +
• Fluoroquinolone (as above)

• Piperacillin-tazobactam 50 mg/kg IV q6h + Enrofloxacin
• Or imipenem 5–10 mg/kg IV q6–8h in refractory sepsis

Note on fluoroquinolones in puppies: Risk of cartilage damage in large breed puppies <8 months. In severe sepsis, the risk-benefit usually favors use. Alternative: gentamicin (only with adequate hydration; nephrotoxic)

---

Nutritional Support

• Evidence shows enteral feeding despite vomiting improves outcomes
• Promotes intestinal mucosal recovery and reduces bacterial translocation
• Nasoesophageal (NE) tube placement should be considered as soon as possible

• Place NE tube; start micro-enteral nutrition at 1 mL/kg/hr of liquid diet
• Gradually increase as tolerated
• If vomiting, reduce rate; do not discontinue
• Preferred diet: commercially balanced liquid diet (e.g., CliniCare Canine/Feline)

---

Oseltamivir (Tamiflu)

• Mechanism: Neuraminidase inhibitor (anti-influenza); proposed benefit in CPV via reducing bacterial overgrowth and endotoxin load
• Dose: 2 mg/kg PO q12h for 5 days
• Evidence: One clinical trial showed improved outcome; subsequent trials have shown mixed results; not universally recommended but some clinicians use it
• Not a direct antiviral against parvovirus

---

Recombinant Feline Interferon Omega (rFeIFN-ω)

• Virbagen Omega (licensed in Europe and Japan, NOT licensed in the US)
• Mechanism: Antiviral; enhances innate immune response
• Dogs: 2.5 MU/kg IV q24h for 3 days (starting as soon as diagnosis confirmed); shows significant improvement in survival in several controlled studies
• Cats: 1 MU/kg IV q24h for 3 days
• Considered the only specific antiviral with proven efficacy; availability limited to countries where licensed

---

Hyperimmune Serum / Anti-CPV Antibodies

• Anti-CPV hyperimmune serum or plasma from immune dogs can be administered
• Theoretical benefit in neutralizing viremia
• Evidence: limited, mixed; not standard of care
• Dose: 1–4 mL/kg IV or SQ if available

---

Management of Specific Complications

• Aggressive fluid resuscitation: 10–20 mL/kg IV crystalloid boluses (reassess after each)
• Vasopressors if unresponsive to fluids: dopamine (5–10 μg/kg/min CRI) or norepinephrine
• Broad-spectrum antibiotics IV

• Fresh Frozen Plasma: 10–20 mL/kg IV
• Heparin: low molecular weight heparin 100–200 U/kg SQ q12h (prophylactic) if early DIC
• Treat underlying disease aggressively

• 0.5–1 mL/kg of 50% dextrose, diluted 1:4 with saline, IV slowly
• Maintain on dextrose-containing fluids

• Surgical correction required
• Must stabilize patient medically before surgery

---

Outpatient / Home Treatment Protocol (when hospitalization is not possible)

• Maropitant 1 mg/kg SQ q24h (given by owner or at clinic)
• Ampicillin or amoxicillin-clavulanate PO (if tolerated)
• Subcutaneous fluids at home: warm LRS, 50–100 mL/kg/day SQ divided q6–12h
• Tamiflu 2 mg/kg PO q12h
• Oral electrolyte solutions if not vomiting
• Daily rechecks for deterioration
• Survival rates lower than hospitalized patients but significantly better than no treatment

---

8. NURSING CARE & ISOLATION

• Strict isolation is mandatory — CPV is highly contagious
• Dedicated protective equipment: gloves, gown, shoe covers
• Hospitalization in isolation ward; separate from other patients
• Bleach (1:30 dilution) for disinfection of cage, floors, equipment (contact time ≥10 minutes)
• Hands: thorough washing + alcohol gel
• Laundry: separate; hot cycle wash
• Staff should not handle vaccinated dogs or cats after handling CPV patients without PPE change
• Cages should be cleaned → disinfected → allowed to dry before reuse

---

9. PROGNOSIS

Canine Parvovirus

• With aggressive hospitalized treatment: survival rate 80–95%
• Without treatment: mortality 70–91%
• Outpatient protocol: survival ~50–80% (resource-limited setting)
• Deaths typically occur within 24–72 hours of hospitalization if they occur

Feline Panleukopenia

• Untreated: mortality up to 90% in young kittens
• With treatment: survival 50–80% depending on severity
• Kittens that survive past 5–7 days have a good prognosis for full recovery
• Surviving kittens with cerebellar hypoplasia have normal life expectancy with appropriate care
• Recovered cats develop long-lasting (likely lifelong) immunity

---

10. PREVENTION & VACCINATION

Canine Parvovirus Vaccination

• Modified-live virus (MLV) vaccines: Generate faster, stronger, and more durable immunity; preferred in most protocols
• Killed/inactivated vaccines: Less immunogenic; require adjuvant; may require more boosters; used where MLV is contraindicated

• Begin at 6–8 weeks of age
• Administer every 2–4 weeks until 16 weeks of age (minimum)
• WSAVA (2016) guidelines: Administer at 6, 10, 16 weeks (or continue every 4 weeks until 16 weeks)
• Final puppy dose must be given at ≥16 weeks of age — critical to overcome maternal antibody interference

• Most important reason for vaccination failure
• Maternal antibodies block vaccine replication and immune response
• MDA wanes to non-interfering levels at different times (varies by litter; range 6–16+ weeks)
• The "window of susceptibility" = period when MDA is too low to protect but too high to allow vaccine to work
• Solution: Extend primary series to 16 weeks; some protocols recommend final dose at 18–20 weeks for high-risk breeds

• 1 year after completion of puppy series
• Then every 3 years (CPV-2 component) — per WSAVA, AAHA guidelines
• MLV CPV vaccines generate immunity lasting ≥3 years (likely much longer, possibly lifetime)

• Anti-CPV antibody titer ≥1:80 (HI) or positive on in-clinic ELISA = protected; no vaccine needed
• Growing acceptance as alternative to routine triennial boosters
• WSAVA supports titer-guided vaccination

Feline Panleukopenia Vaccination

• Begin at 6–8 weeks
• Every 3–4 weeks until ≥16 weeks
• MLV vaccines: one dose post-maternal antibody waning is highly effective

• 1 year after kitten series
• Then every 3 years

---

11. ENVIRONMENTAL DECONTAMINATION

• CPV/FPV survive on surfaces for months to years
• Standard cleaning with soap and water: removes organic matter but does NOT inactivate virus
• Effective disinfectants:

• Premises that housed a CPV/FPV-positive animal should be considered contaminated for ≥1 year
• Before introducing new unvaccinated puppies/kittens, decontaminate thoroughly and ideally allow adequate time

---

12. SPECIAL POPULATIONS

Shelter Medicine

• Parvoviruses are the #1 infectious disease emergency in shelters
• Exposure protocol: Immediately quarantine exposed animals; vaccinate all exposed unvaccinated animals immediately (reduces severity even if already exposed)
• Outbreak management: Quarantine entire affected population; suspend intake; aggressive decontamination; cohort management

Immunocompromised Animals

• FeLV/FIV-positive cats: higher severity and mortality from FPV
• Dogs on immunosuppressive therapy: may fail to respond adequately to vaccination; also at higher risk of vaccine-induced disease with MLV
• Canine distemper-affected puppies: concurrent parvovirus common; worse prognosis

Wildlife and Zoo Animals

• FPV infects wild felids (lions, tigers, leopards, cheetahs) — significant conservation concern
• Mink are highly susceptible to FPV (Aleutian disease virus in mink is a different parvovirus)
• Raccoons: susceptible to both FPV and CPV; can act as reservoirs
• Vaccination of captive wild felids with killed FPV vaccine recommended

---

13. SUMMARY COMPARISON TABLE

---

14. KEY POINTS FOR CLINICAL PRACTICE

1. Any unvaccinated puppy or kitten with acute vomiting + diarrhea should be considered parvovirus until proven otherwise.
2. Leukopenia/lymphopenia on CBC is a cardinal early finding — run a CBC on every suspect case.
3. Fecal ELISA is the first-line test; follow up with PCR if negative but suspicion remains high.
4. Aggressive IV fluid therapy is the single most important therapeutic intervention.
5. Early enteral nutrition (NE tube) significantly improves outcomes — start as soon as possible.
6. Isolation is non-negotiable — parvovirus is one of the most environmentally stable and contagious pathogens in veterinary medicine.
7. The final puppy vaccine dose at ≥16 weeks is the most critical dose in the series due to maternal antibody interference.
8. Bleach (1:30) and AHP are the only practical effective disinfectants.
9. Rottweilers and Dobermans require special attention — they may not mount adequate immune responses even after vaccination; some clinicians recommend extending the puppy series or titer checking.
10. Cerebellar hypoplasia in kittens is permanent but non-progressive — do not euthanize based on diagnosis alone.

---

• Canine Parvovirus (dogs only)
• Feline Panleukopenia (cats only)